丙型肝炎治疗药物研究进展  

Progress in Research on Therapeutic Drugs for Hepatitis C

作　　者：童叶萌 李盏 蔡昆[3] 刘爽[3] 王雷[3] 童叶青[3] Tong Yemeng;Li Zhan;Cai Kun;Liu Shuang;Wang Lei;Tong Yeqing(Wuhan Prevention and Treatment Center for Occupational Diseases,Wuhan 430015,China;School of Public Health,Tongji Hospital,Huazhong University of Science and Technology;Hubei Provincial Center for Disease Control and Prevention)

机构地区：[1]武汉市职业病防治院,武汉430015 [2]华中科技大学同济公共卫生学院 [3]湖北省疾病预防控制中心

出　　处：《药物流行病学杂志》2019年第7期468-471,共4页Chinese Journal of Pharmacoepidemiology

基　　金：湖北省创新技术专项(编号:2017ADC061)

摘　　要：丙肝病毒(HCV)感染是一个全球公共卫生热点问题,感染丙肝后慢性化概率极高,容易并发肝硬化等并发症,严重危害身体健康。近年,随着直接抗病毒治疗药物(DAAs)的诞生和发展,为慢性丙型肝炎(CHC)治疗带来了福音,当前泛基因型直接抗病毒药物是当前丙肝治疗的发展趋势。目前国际上已上市的DAAs主要有特拉瑞韦(telaprevir)、波塞瑞韦(boceprevir)、达卡他韦(daclatasvir)、索磷布韦(sofosbuvir)、西米匹韦(simeprevir);含2种及以上靶点抑制药组成的固定复方制剂主要有哈维尼(harvoni)、伊柯鲁沙(epclusa)等。本文主要综述近年来DAAs的研发进展,以期为CHC防治提供依据。Hepatitis C virus ( HCV) infection is a global public health hotspot. The probability of chronic hepatitis C infection is extremely high,and it is easy to complicated with complications such as cirrhosis,which seriously endangers health. In recent years,with the birth and development of direct antiviral drugs ( DAAs),it has brought good news for the treatment of chronic hepatitis C ( CHC). The current pan-genotype direct antiviral drugs are the current development trend of hepatitis C treatment. At present,DAAs currently listed in the world mainly include telaprevir/incivek,boceprevir,daclatasvir,sofosbuvir ( SOF) and simeprevir;fixed combination preparations containing two or more target inhibitors are mainly harvoni,epclusa and so on. This article mainly reviews the development of anti-viral drugs for hepatitis C and the progress of drug research at home and abroad,in order to provide a basis for the prevention and treatment of hepatitis C in the same industry.

关 键 词：丙型肝炎 抗病毒治疗药物 研究进展 

分 类 号：R978.7[医药卫生—药品]